These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 29227461)
1. Population Pharmacokinetics of Lopinavir in Severely Malnourished HIV-infected Children and the Effect on Treatment Outcomes. Archary M; Mcllleron H; Bobat R; La Russa P; Sibaya T; Wiesner L; Hennig S Pediatr Infect Dis J; 2018 Apr; 37(4):349-355. PubMed ID: 29227461 [TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus-infected children in relation to treatment outcomes. Archary M; Mcllleron H; Bobat R; LaRussa P; Sibaya T; Wiesner L; Hennig S Br J Clin Pharmacol; 2019 Sep; 85(9):2066-2075. PubMed ID: 31141195 [TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of rifabutin among HIV/TB co-infected children on lopinavir/ritonavir-based antiretroviral therapy. Semere Gebreyesus M; Wasmann RE; McIlleron H; Oladokun R; Okonkwo P; Wiesner L; Denti P; Rawizza HE Antimicrob Agents Chemother; 2024 Aug; 68(8):e0035424. PubMed ID: 39037240 [TBL] [Abstract][Full Text] [Related]
4. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial. Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V; BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406 [TBL] [Abstract][Full Text] [Related]
5. Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV. Niu WJ; Sun T; Liu L; Liu XQ; Zhang RF; Yin L; Wang JR; Jia XF; Lu HZ; Zhong MK; Jiao Z; Zhang LJ Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):456-465. PubMed ID: 30346663 [TBL] [Abstract][Full Text] [Related]
6. Abacavir Exposure in Children Cotreated for Tuberculosis with Rifampin and Superboosted Lopinavir-Ritonavir. Rabie H; Tikiso T; Lee J; Fairlie L; Strehlau R; Bobat R; Liberty A; McIlleron H; Andrieux-Meyer I; Cotton M; Lallemant M; Denti P Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32071055 [TBL] [Abstract][Full Text] [Related]
7. CYP3A5, ABCB1, and SLCO1B1 polymorphisms and pharmacokinetics and virologic outcome of lopinavir/ritonavir in HIV-infected children. Rakhmanina NY; Neely MN; Van Schaik RH; Gordish-Dressman HA; Williams KD; Soldin SJ; van den Anker JN Ther Drug Monit; 2011 Aug; 33(4):417-24. PubMed ID: 21743379 [TBL] [Abstract][Full Text] [Related]
9. The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda. Bartelink IH; Savic RM; Dorsey G; Ruel T; Gingrich D; Scherpbier HJ; Capparelli E; Jullien V; Young SL; Achan J; Plenty A; Charlebois E; Kamya M; Havlir D; Aweeka F Pediatr Infect Dis J; 2015 Mar; 34(3):e63-70. PubMed ID: 25742090 [TBL] [Abstract][Full Text] [Related]
10. Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis. Chaivichacharn P; Avihingsanon A; Gatechompol S; Ubolyam S; Punyawudho B Drug Metab Pharmacokinet; 2022 Dec; 47():100478. PubMed ID: 36375225 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of pediatric lopinavir/ritonavir tablets in children when administered twice daily according to FDA weight bands. Bastiaans DE; Forcat S; Lyall H; Cressey TR; Hansudewechakul R; Kanjanavanit S; Noguera-Julian A; Königs C; Inshaw JR; Chalermpantmetagul S; Saïdi Y; Compagnucci A; Harper LM; Giaquinto C; Colbers AP; Burger DM; Pediatr Infect Dis J; 2014 Mar; 33(3):301-5. PubMed ID: 24356253 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092. Owor M; Tierney C; Ziemba L; Browning R; Moye J; Graham B; Reding C; Costello D; Norman J; Wiesner L; Hughes E; Whalen ME; Purdue L; Mmbaga BT; Kamthunzi P; Kawalazira R; Nathoo K; Bradford S; Coletti A; Aweeka F; Musoke P Pediatr Infect Dis J; 2021 May; 40(5):446-452. PubMed ID: 33464021 [TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes for HIV-infected infants less than 6 months of age at initiation of lopinavir/ritonavir combination antiretroviral therapy. Chadwick EG; Yogev R; Alvero CG; Hughes MD; Hazra R; Pinto JA; Robbins BL; Heckman BE; Palumbo PE; Capparelli EV; AIDS; 2011 Mar; 25(5):643-9. PubMed ID: 21297419 [TBL] [Abstract][Full Text] [Related]
14. Sex differences in responses to antiretroviral treatment in South African HIV-infected children on ritonavir-boosted lopinavir- and nevirapine-based treatment. Shiau S; Kuhn L; Strehlau R; Martens L; McIlleron H; Meredith S; Wiesner L; Coovadia A; Abrams EJ; Arpadi SM BMC Pediatr; 2014 Feb; 14():39. PubMed ID: 24521425 [TBL] [Abstract][Full Text] [Related]
15. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age. Penazzato M; Prendergast AJ; Muhe LM; Tindyebwa D; Abrams E Cochrane Database Syst Rev; 2014 May; 2014(5):CD004772. PubMed ID: 24852077 [TBL] [Abstract][Full Text] [Related]
16. Coadministration of lopinavir/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa. Murphy RA; Marconi VC; Gandhi RT; Kuritzkes DR; Sunpath H PLoS One; 2012; 7(9):e44793. PubMed ID: 23028623 [TBL] [Abstract][Full Text] [Related]
17. Antiretroviral therapy outcomes in HIV-infected children after adjusting protease inhibitor dosing during tuberculosis treatment. Frohoff C; Moodley M; Fairlie L; Coovadia A; Moultrie H; Kuhn L; Meyers T PLoS One; 2011 Feb; 6(2):e17273. PubMed ID: 21383838 [TBL] [Abstract][Full Text] [Related]
18. Abacavir pharmacokinetics in African children living with HIV: A pooled analysis describing the effects of age, malnutrition and common concomitant medications. Tikiso T; McIlleron H; Burger D; Gibb D; Rabie H; Lee J; Lallemant M; Cotton MF; Archary M; Hennig S; Denti P Br J Clin Pharmacol; 2022 Feb; 88(2):403-415. PubMed ID: 34260082 [TBL] [Abstract][Full Text] [Related]
19. Population Pharmacokinetics of Lopinavir/Ritonavir: Changes Across Formulations and Human Development From Infancy Through Adulthood. Yang J; Nikanjam M; Best BM; Pinto J; Chadwick EG; Daar ES; Havens PL; Rakhmanina N; Capparelli EV J Clin Pharmacol; 2018 Dec; 58(12):1604-1617. PubMed ID: 30252146 [TBL] [Abstract][Full Text] [Related]
20. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations. Bouazza N; Foissac F; Fauchet F; Burger D; Kiechel JR; Treluyer JM; Capparelli EV; Lallemant M; Urien S Antivir Ther; 2015; 20(2):225-33. PubMed ID: 25279808 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]